Puma Biotech (PBYI) Announces Submission of PB272 NDA to FDA for Extended Adjuvant Treatment in Certain Breast Cancer Patients
Tweet Send to a Friend
Puma Biotechnology, Inc. (NYSE: PBYI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
